Penetration of idarubicin into malignant brain tumor tissue - PubMed (original) (raw)

Clinical Trial

Penetration of idarubicin into malignant brain tumor tissue

W Boogerd et al. J Neurooncol. 1999 Aug.

Abstract

Anthracyclines are effective in breast cancer and have in vitro cytotoxicity in glioma. In patients with glioma anthracyclines are not effective possibly because the hydrophilic drugs do not reach cytotoxic levels in tumor tissue. Idarubicin is more lipophilic than the other anthracyclines and is more cytotoxic in glioma cell lines. The uptake of idarubicin and its major metabolite idarubicinol in brain tumor tissue were measured in a patient with a brain metastasis from breast cancer and in 4 patients with malignant glioma after an oral dose of idarubicin (45 mg/m2 in 1 patient; 25 mg/m2 in 4 patients), given 15-24 h before brain tumor resection. The concentrations of idarubicin and of idarubicinol in tumor tissue exceeded the concurrent plasma concentrations as well as the peak plasma concentrations in all cases. The median tumor:concurrent plasma ratio of idarubicinol was 5.7 (range 1.7-18). The concentration of idarubicinol in the marginal zone between brain and tumor tissue was lower than in central tumor tissue, but was still higher than the plasma concentration in 2 of the 3 examined cases. Bone marrow suppression (platelets CTC grade 2, granulocytes CTC grade 4) occurred after a single dose of 45 ml/m2. No toxicity was seen at a dose of 25 mg/m2. These results, the in vitro activity of idarubicin in glioma, the convenience of oral administration, and its toxicity profile make clinical studies with idarubicin in malignant glioma, and perhaps also in brain metastases from breast cancer worthwhile.

PubMed Disclaimer

Cited by

Sensitive Analysis of Idarubicin in Human Urine and Plasma by Liquid Chromatography with Fluorescence Detection: An Application in Drug Monitoring.
Maliszewska O, Treder N, Olędzka I, Kowalski P, Miękus N, Bączek T, Rodzaj W, Bień E, Krawczyk MA, Plenis A. Maliszewska O, et al. Molecules. 2020 Dec 9;25(24):5799. doi: 10.3390/molecules25245799. Molecules. 2020. PMID: 33316898 Free PMC article.
Identification of a novel glioblastoma multiforme molecular subtype with poor prognosis and high immune infiltration based on oxidative stress-related genes.
Huang G, Hou X, Li X, Yu Y, Ge X, Gan H. Huang G, et al. Medicine (Baltimore). 2024 Feb 16;103(7):e35828. doi: 10.1097/MD.0000000000035828. Medicine (Baltimore). 2024. PMID: 38363895 Free PMC article.
Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma.
Chehimi M, Boone M, Chivot C, Deramond H, Constans JM, Ly MC, Chauffert B. Chehimi M, et al. Case Rep Oncol. 2016 Aug 30;9(2):499-505. doi: 10.1159/000448654. eCollection 2016 May-Aug. Case Rep Oncol. 2016. PMID: 27721775 Free PMC article.
An Insight into Pathophysiological Features and Therapeutic Advances on Ependymoma.
Seo SH, Paul SK, Shikder M, Khanam M, Ghosh P, Hasib TA, Ahmed KA, Sikdar S, Uddin MJ, Kwon Y. Seo SH, et al. Cancers (Basel). 2021 Jun 28;13(13):3221. doi: 10.3390/cancers13133221. Cancers (Basel). 2021. PMID: 34203272 Free PMC article. Review.
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD. Morikawa A, et al. Neuro Oncol. 2015 Feb;17(2):289-95. doi: 10.1093/neuonc/nou141. Epub 2014 Jul 11. Neuro Oncol. 2015. PMID: 25015089 Free PMC article.

References

1. Br J Cancer. 1996 Jul;74(2):187-93 - PubMed
1. Med Pediatr Oncol. 1996 Dec;27(6):505-14 - PubMed
1. Acta Neurochir (Wien). 1990;104(1-2):13-6 - PubMed
1. Chem Pharm Bull (Tokyo). 1988 Sep;36(9):3503-11 - PubMed
1. J Clin Oncol. 1992 Sep;10(9):1498-502 - PubMed

Penetration of idarubicin into malignant brain tumor tissue - PubMed (original) (raw)